Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
DaraVRD for Multiple Myeloma
Recruiting3 awardsPhase 2
Birmingham, Alabama
This trial is testing whether using a next generation sequencing test to check for minimal residual disease can help doctors decide when to do an autologous hematopoietic stem cell transplant for people with newly diagnosed multiple myeloma.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.